Quilizumab

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameQuilizumab
Drug Alias NameAnti M1 prime monoclonal antibody奎利珠单抗奎利组单抗quilizumabumRG-7449 +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionImmunoglobulin E inhibitors
TargetsImmunoglobulin E
Therapy Area/IndicationsUrticariaRhinitis, AllergicAsthma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumBulgariaCanada +[15] 
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGenentech Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGenentech Inc
Active IndicationsN/A
Inactive IndicationsUrticariaRhinitis, AllergicAsthma

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG